A phase 3, randomized, open-label study to compare the efficacy of tislelizumab (BGB-A317) versus chemotherapy as second-line therapy for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC).

作者:Lin, Shen; Jaffer A., Ajani; Sung-Bae, Kim; Eric, Van Cutsem; Baohong, Guo; James, Song; Virginia, Paton; Ken, Kato
来源:Journal of Clinical Oncology, 2018, 36(15_suppl): TPS3111-TPS3111.
DOI:10.1200/jco.2018.36.15_suppl.tps3111
  • 出版日期2018-5-20
  • 单位The university of Texas,M.D.Anderson Cancer Center; University of Texas M. D. Anderson Cancer Center; University of Texas M.D.Anderson Cancer Center; the university of Texas MD Anderson Cancer Center; The University of Texas M.D Anderson Cancer Center; University of Texas, M.D. Anderson Cancer Center; The University of Texas M.D.Anderson Cancer Center; University of Texas M.D.Anderson cancer center; The University of Texas MD Anderson Cancer Center; The University of Texas M.D anderson Cancer Center; University of Texas,M.D.Anderson Cancer Center; 北京大学; University Of Texas MD Anderson Cancer Center; University of Texas M.D. Anderson Cancer Center; The University of Texas MD, Anderson Cancer Center; UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER; University of Texas, MD Anderson Cancer Center; The University of Texas, MD Anderson Cancer Center

全文